Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Alkermes' Stock Is Tanking Today

By George Budwell - Jan 21, 2016 at 11:13AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The news that the drugmaker's lead experimental product for major depressive disorder failed to meet its primary endpoints in two late-stage studies sent shares south.

Image source: Pixabay.

What: Shares of Alkermes (ALKS 2.63%) shed up to 43% of their value on extraordinary volume in early morning trading today after the company announced that its orally administered drug ALKS-5461, indicated for major depressive disorder (MDD), failed to meet its primary endpoints in two late-stage studies. The drug is presently in a third late-stage study, and Alkermes said it plans on updating investors on the progress of this remaining study later this year. 

So what: According to analysts polled by S&P Capital IQ, peak sales for ALKS-5461 as a treatment for MDD in patients that fail to respond to the current generation of available medicines could have reached into the $500 million range -- that is, before today's disappointing news. After all, nearly 7 million out of the 11 million patients taking anti-depressants for MDD fail to respond to any commercially available therapy.  

Now what: Alkermes reported that a post-hoc analysis revealed that the entire 2 mg/2 mg dosing group in the so-called "FORWARD-4" study reached statistical significance in terms of reducing symptoms associated with MDD when compared to patients taking placebo.

While that's good news, it's important to keep in mind that this result can't be taken as direct evidence of the drug's efficacy. Investors are therefore going to have to wait for the final ongoing study to wrap up in order to get any real insight into ALKS-5461's fate as a treatment for MDD.

Having said that. these initial late-stage results don't bode well for the drug's development for this indication, meaning that investors probably shouldn't give it too much weight as they start to revise their valuation models today. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alkermes plc Stock Quote
Alkermes plc
ALKS
$29.69 (2.63%) $0.76

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
338%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.